Alimera Announces Scientific Data Highlighting YUTIQ to Be Presented at Upcoming Association for Research in Vision and Ophthalmology and Retina World Congress Conferences
ATLANTA, May 07, 2024 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) ("Alimera"), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners co
Alimera Sciences to Report First Quarter 2024 Financial Results on May 14, 2024, and Provide Corporate Update
ATLANTA, April 30, 2024 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) (Alimera), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal
323 drugs, hurry up! America is facing the biggest “drug shortage” in history...
The US now seems to be facing an unprecedented “drug shortage”...
Alimera Sciences Initiated at Buy by Maxim Group
Alimera Sciences Initiated at Buy by Maxim Group
Maxim Group Initiates Coverage On Alimera Sciences With Buy Rating, Announces Price Target of $10
Maxim Group analyst Naz Rahman initiates coverage on Alimera Sciences with a Buy rating and announces Price Target of $10.
The Top Stocks With Buying Pressure Across the Russell Universe - Jefferies
Alimera Sciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
ATLANTA, March 20, 2024 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) ("Alimera" or the "Company"), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners
Alimera Announces First Patient Randomized In Radiation Retinopathy Trial Being Conducted By The DRCR Retina Network
Alimera Announces First Patient Randomized In Radiation Retinopathy Trial Being Conducted By The DRCR Retina Network
Alimera Sciences Is Maintained at Buy by HC Wainwright & Co.
Alimera Sciences Is Maintained at Buy by HC Wainwright & Co.
HC Wainwright & Co. Maintains Buy on Alimera Sciences, Raises Price Target to $6
HC Wainwright & Co. analyst Yi Chen maintains Alimera Sciences with a Buy and raises the price target from $5 to $6.
Alimera Sciences Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 03/08/2024 51.9% HC Wainwright & Co. $5 → $6 Maintains Buy 08/14/2023 26.58% HC Wainwright & Co. → $5 Reit
Buy Rating Affirmed for Alimera Sciences Amid Strong Financial Performance and Promising Clinical Trials
Earnings Call Summary | Alimera Sciences(ALIM.US) Q4 2023 Earnings Conference
The following is a summary of the Alimera Sciences, Inc. (ALIM) Q4 2023 Earnings Call Transcript:Financial Performance:Alimera Q4 2023 reported a consolidated global net revenue of $26.3 million, up 8
Alimera Sciences Sees 2024 Adjusted Ebitda Margin Topping 20% >ALIM
Alimera Sciences Sees 2024 Adjusted Ebitda Margin Topping 20% >ALIM
Alimera Sciences Q4 EPS $(0.07) Up From $(0.54) YoY, Sales $26.31M Beat $24.34M Estimate
Alimera Sciences (NASDAQ:ALIM) reported quarterly losses of $(0.07) per share. This is a 87.04 percent increase over losses of $(0.54) per share from the same period last year. The company reported q
Alimera Sciences 4Q Rev $26.3M >ALIM
Alimera Sciences 4Q Rev $26.3M >ALIM
Press Release: Alimera Sciences Reports Fourth Quarter and Full Year 2023 Results
Alimera Sciences Reports Fourth Quarter and Full Year 2023 Results Q4 Net Revenues up 88% to $26.3 million vs. Q4 2022 2023 Net Revenues up 49% to $80.8 million vs. 2022 Increases 2024 Revenue Guid
Earnings Scheduled For March 7, 2024
Companies Reporting Before The Bell • CI&T (NYSE:CINT) is estimated to report quarterly earnings at $0.06 per share on revenue of $106.08 million. • Stevanato Gr (NYSE:STVN) is likely to report quarte
Alimera Sciences Q4 2023 Earnings Preview
Alimera Sciences to Report Fourth Quarter and Full Year 2023 Financial Results on March 7, 2024, and Provide Corporate Update
ATLANTA, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) (Alimera), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal
No Data